Press Releases

Research and Markets: DRG Insights: Hepatitis C (G7)

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "DRG Insights: Hepatitis C (G7)" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Hepatitis C virus (HCV) is marked by a relatively large prevalent population and high unmet medical need due to the suboptimal efficacy of current therapy.

This high unmet need makes HCV one of the most active areas of drug development within infectious diseases. The protease and polymerase inhibitors are the most promising classes in development, and we anticipate these agents will change the standard of care soon after they are introduced into the market.

We expect the HCV market to greatly expand in the coming years due, in large measure, to the entry of novel drugs and their impact on both treatment rates and the re-treatment of nonresponders.

Key Topics Covered:

Executive Summary Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies

Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet Needs

Emerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions


2010 and 2010 sales and Market Share

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets